Medical Advocates
Enfuvirtide [T-20] (Fuzeon)
 
Archived Conference Citations


42 IDSA Annual Meeting
2004 National ADAP Educational Conference
11th CROI
 XII International HIV Drug Workshop
1st European HIV Drug Resistance Workshop
 XIV International AIDS Conference


 
Enfuvirtide Main Page Conferences Main Page Home Page      
Last Update:  February 26, 2008
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
42 IDSA Annual Meeting
 
  NEWS RELEASE
 Fuzeon Plus an Active Boosted Protease Inhibitor Doubles Long-Response in Treatment-
Experienced HIV Patients 
October 05, 2004
 PDF News Release
 
  POSTER
 Virologic Suppression of an Active Boosted PI Regimen is Significantly Enhanced
by the Addition of a Fusion Inhibitor in Treatment-Experienced Patients
 GD Miralles ,RA DeMasi  
Poster
2004 National ADAP Educational Conference
 
  PRESENTATION
 Evaluating the Patient for Fusion Inhibitors
 Steinhart C
 National ADAP Educational Conference May 20-21, 2004
 PDF Oral Presentation
11th Conference on Retroviruses and Opportunistic
Infections
  POSTER
 24-week Safety and Efficacy of Enfuvirtide as Part of an Optimized Antiretroviral
Regimen in Adolescents
A Wiznia, J Church, J Stavola, et al
PDF Poster    Abstract

POSTER
 The Effects of Enfuvirtide Therapy on Body Composition and Serum Lipids through
48 Weeks in the TORO Trials
DA Cooper, P Reiss, K Henry, et al
PDF Poster      Abstract

Evolution of HR1 and HR2 Mutations in HIV-1 gp41 Associated with Long-term
Enfuvirtide Therapy
 L Xu, A Pozniak, A Wildfire, et al.
Abstract

Genetic and Phenotypic Characteristics of Enfuvirtide-resistant HIV-1 Isolates Evolved
in vivo after Long-term Treatment
 A Monachetti, A Castagna, P Bagnarelli, et al.  
Abstract
2nd IAS Conference on Pathogenesis and Treatment
 
 

ANALYSIS OF PATIENT-DERIVED HIV-1 ISOLATES SUGGESTS A NOVEL MECHANISM FOR
DECREASED SENSITIVITY TO INHIBITION BY ENFUVIRTIDE AND T-649
M Heil, J Decker, DT. Chen, et al.
 Abstract

IMPACT OF ENFUVIRTIDE ON HEALTH-RELATED QUALITY OF LIFE
 CJ  Cohen, N Clumeck, JM Molina, et al.
 Abstract
 
CLINICAL PROGNOSIS OF ENFUVIRTIDE IN COMBINATION WITH AN OPTIMIZED
BACKGROUND REGIMEN AMONG CATEGORIES OF BASELINE CD4+ CELL COUNT
AND HIV ANTIRETROVIRAL RESISTANCE
J Hornberger-, J Green
 Abstract
 
IMPACT OF VIRAL GENOTYPE AND PHENOTYPE ON ENFUVIRTIDE RESPONSE IN HIV-I
NFECTED PATIENTS
E Poveda, B Rodés, MA Muñoz-Fernández, et al
 Abstract
 
ANALYSIS OF VIROLOGICAL RESPONSE OF ENFUVIRTIDE IN TORO: IMPLICATIONS FOR
PATIENT MANAGEMENT
J Montaner, R DeMasi, J Delehanty, et al
 Abstract
 
PHARMACOKINETICS OF ENFUVIRTIDE IN PEDIATRIC HIV INFECTED PATIENTS RECEIVING
COMBINATION THERAPY
SE Bellibas, Z Siddique, A.Dorr, et al
 Abstract
 
ENFUVIRTIDE TORO STUDIES: 48 WEEK RESULTS CONFIRM 24 WEEK FINDINGS 
[No authors listed]
 Abstract
 
Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients
with prior experience or resistance to each of the three classes of approved antiretrovirals (ARVs) in
Europe and Australia.
B Clotet, A Lazzarin, D Cooper, et al
 Abstract
 
IMPACT OF VIRAL GENOTYPE AND PHENOTYPE ON ENFUVIRTIDE RESPONSE IN HIV-
INFECTED PATIENTS
E Poveda, B Rodés, MA.Muñoz-Fernández, et al
 Abstract
 
ANALYSIS OF VIROLOGICAL RESPONSE OF ENFUVIRTIDE IN TORO: IMPLICATIONS FOR
PATIENT MANAGEMENT
J Montaner, R DeMasi, J Delehanty, et al
 Abstract
 
PHARMACOKINETICS OF ENFUVIRTIDE IN PEDIATRIC HIV INFECTED PATIENTS RECEIVING
COMBINATION THERAPY
SE Bellibas, Z Siddique, A Dorr, et al
 Abstract
XII International HIV Drug Resistance Workshop
 
 
POSTER
 Baseline and on-treatment gp41 genotype and susceptibility to enfuvirtide (ENF) and
T-1249 in a 10-day study of T-1249 in patients failing an ENF-containing regimen
(T1249-102)
GD Miralles, Melby, R DeMasi,et al.
PDF Poster

POWER-POINT PRESENTATION
 The Relationship between Susceptibility to Enfuvirtide of Baseline Viral Recombinants and
Polymorphisms in the Env Region of R5-tropic HIV-1
C. Su, G. Heilek-Snyder, D. Fenger, et al.
Presentation       Abstract

POSTER
 Subgroup analysis of baseline susceptibility and early virological response to enfuvirtide in
 the combined TORO studies
 P Sista, T Melby, ML Greenberg, et al
PDF Poster

POSTER
 Determinants of susceptibility to enfuvirtide map to gp41 in enfuvirtide-naive HIV-1
SA Stanfield-Oakley, J Jeffrey, CB McDanal, et al.
 PDF Poster

Mechanisms underlying a sustained CD4 T cell recovery despite the emergence of resistance in
antiretroviral-experienced patients on prolonged enfuvirtide treatment
 E Poveda, B Rodés, JM Benito, et al
Abstract
lst European HIV Drug Resistance Workshop
 
  POSTER
 Uncommon gp41 variants at residue positions critical for Enfuvirtide (T-20) resistance in
Enfuvirtide-naïve patients infected with subtype B and NON-B HIV-1.
Roman F, Gonzalez D, Lambert C , et al.
 PDF Poster
   
  POSTER
 Enfuvirtide Baseline (BL) and on-Treatment Susceptibility:Week 24 analysis in TORO 1
and TORO 2
N Cammack, M Greenburg, T Melby, et al
 PDF Poster
   
  POWER-POINT PRESENTATION
 Quantitative assessment of resistance to fusion inhibitors in a replicative Phenotyping
assay.
 V Brondani, F Hamy, T  Klimkait 
 Presentation
XIV International AIDS Conference
 
  Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB
alone in patients with prior experience or resistance to each of the three classes of
approved antiretrovirals (ARVs) in Europe and Australia.
B Clotet, A Lazzarin, D Cooper, et al
 Abstract
 
Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs.
OB alone in patients with prior experience or resistance to each of the three
classes of approved antiretrovirals (ARVs) in North America and Brazil.
K Henry, J Lalezari, M O'Hearn, et al
 Abstract

Enfuvirtide Main Page Conferences Main Page Home Page      

Archived Enfuvirtide Conference Citations

-